Dysfunction of Dendritic and T Cells as the Cause of Immune Suppression in HTLV-I Infected Individuals

Ziyad Mutlaq Al-Dahoodi1, Shigeki Takemoto1, Sayo Kataoka2 and Hirokuni Taguchi3

Human T lymphotropic virus type I (HTLV-I) impairs cellular immunity and can develop into adult T cell leukemia/lymphoma (ATLL). The Role of dendritic cells (DC) has not been fully elucidated in individuals infected by HTLV-I. To address this issue, we studied several cellular parameters, including phenotypic and functional characteristics of monocyte-derived DC. Generated DC exhibited down-regulation in the expression of CD1a and HLA-DR in HTLV-I carriers, suggesting partial impairment of maturation. T cells were stimulated by autologous DC in half of HTLV-I carriers, as well as healthy donors, but not in ATLL patients. Because of the importance of CD40-CD40 ligand (CD40L) signaling in establishing an inflammatory immune response, we also investigated the expression of soluble CD40L (sCD40L) of PHA-activated lymphocytes from HTLV-I infected individuals. sCD40L was detected in the culture supernatant of lymphocytes from one of four HTLV-I carriers investigated. These results suggest that the defect or aberration in the function of DC and the expression of sCD40L in T cells is associated with immune suppression in HTLV-I infected individuals.

INTRODUCTION

Human T lymphotropic virus type I (HTLV-I) is the cause of adult T cell leukemia/lymphoma (ATLL), and some non-malignant diseases1–3. During the asymptomatic stage of HTLV-I infection, the number of infected T cells is probably restricted by viral antibodies and cytotoxic T lymphocytes (CTL)4. However, once clonal proliferation of HTLV-I infected cells is detected following impairment of cellular immunity in HTLV-I carriers5–7, ATLL develops in only a small portion. Dendritic cells (DC) are considered the most potent antigen-presenting cells (APC) and they can stimulate naive and memory CD4+ and CD8+ T cells. Inflammatory cytokines, such as IL-1 and tumor necrosis factor-alpha (TNF-α), as well as cell to cell contact with activated T cells through CD40 ligand (CD40L) induces DC to mature8–10. A recent study has shown that CD40L expression by CD4+ T cells is critical to elicit cell-mediated immune responses11. Impaired APC function or the generation of inappropriate APC are possible mechanisms that lead to development of immune suppression. Compared to normal controls, phenotypic expression and function of monocyte-derived DC were impaired in diabetes mellitus and myelodysplastic syndrome patients12–13. Dysfunction of DC also has been reported in ATLL patients14. There is emerging evidence that malignant cells may be able to escape from anti-tumor immune responses by inhibiting the differentiation or the function of APC15,16. Because the role of DC has not been fully elucidated in HTLV-I carriers, we investigated monocyte-derived DC obtained from asymptomatic HTLV-I carriers, as well as from ATLL patients.

---

Received: Oct 29, 2002
Revised: Nov 18, 2002
Accepted: Nov 22, 2002

1The Third Department of Internal Medicine, 2Medical Research Center, Kochi Medical School, Nankoku-city, Kochi 783-8565, Japan
Address correspondence and reprint request to Shigeki Takemoto, The Third Department of Internal Medicine, Kochi Medical School, Kohasu, Oko-cho, Nankoku-city, Kochi 783-8565, Japan
MATERIALS AND METHODS

Patient samples and dendritic cell generation

Peripheral blood was donated after informed consent by 4 patients diagnosed with ATLL (3 acute type and 1 lymphoma type), and 3 healthy donors at Kochi Medical School. Auffy coat fraction from 6 HTLV-I infected blood donors was prepared at Kochi Red Cross Blood Center and used for evaluation of asymptomatic HTLV-I carriers. We have no information on them.

Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood by density-gradient centrifugation using Ficoll-Hypaque and were used immediately or cryopreserved in liquid nitrogen until use, as described below. Monocytes were isolated with beads coated with anti-CD14 mAb (Dynabeads 450, Dynal, Oslo, Norway). Isolated monocytes were cultured at a density of 1 x 10⁶ cells/ml in a RPMI-1640 medium for 5 days. The medium was supplemented with 2 mM L-glutamine, 100 μg/ml of streptomycin, 100 U/ml of penicillin G and 10% heat-inactivated fetal bovine serum (FBS). 50 ng/ml of GM-CSF and 10 ng/ml of IL-4 (both from Sigma, Saint Louis, MO, USA) were supplied every two days. Maturation of differentiated DC was accomplished by treating with TNF-α (10 ng/ml) (Sigma) for another 2 days in the presence of IL-4 and GM-CSF. Cell differentiation was morphologically monitored after May-Giemsa staining.

Flow cytometry analysis

The surface phenotype expression of immature and mature DC was examined using a four color analyzer (FACSCalibur, Becton Dickinson, San Jose, CA, USA). The following commercially available directly conjugated monoclonal antibodies were used: CD1a mAb, CD11c mAb CD40 mAb, CD80 mAb, CD86 mAb and HLA-DR mAb (all from eBioscience, San Diego, CA, USA). Appropriate isotype-matched negative controls were used for comparison. Viable cells (1 x 10⁶) were gated and analyzed.

Assay of endocytosis

The ability of DC endocytosis was assessed using fluorescein isothiocyanate (FITC)-conjugated dextran (Sigma). After cells were harvested and re-suspended in RPMI-1640 medium, FITC-dextran (MW 40000) was added at a final concentration of 1 mg/ml. Cells were incubated at 37°C for 1 h, washed four times with cold phosphate-buffered saline and analyzed by flow cytometry.

Cell proliferation assay

Autologous DC-lymphocyte mixed culture was conducted. Mature DC were harvested and used as stimulator cells after irradiation (30 Gy) (Gamma cell, Ontario, Canada). Autologous lymphocytes, after removal of monocytes from PBMC, were treated with purified phytohemagglutinin (PHA-P, 5 μg/ml, Difco, Detroit, MI, USA) for 3 days and IL-2 (10 U/ml, kindly provided by Dr G Franchini, NCI/NIH, Bethesda, MD, USA) for another 4 days and used as responder cells. Stimulator and responder cells were plated in a ratio of 1: 10 in 96-well round-bottom tissue culture plates (Costar, NY, USA). Proliferation of stimulator cells was completely blocked by irradiation. Cultures were maintained in a humidified atmosphere at 37°C and 5% CO₂. Thymidine incorporation was measured after 4-day incubation by pulsing for 18 h with 1 μCi/well of ³H-thymidine. The results were expressed as the mean difference in counts per minute obtained from triplicate cultures using a liquid scintillation counter.

Measurement of soluble CD40 ligand (sCD40L) in cell culture supernatants

After positive selection of monocytes from PBMC, as described above, remaining lymphocytes and lymph node (LN) cells from lymphoma-type patients, as well as a MT-2 cell line, were cultured (1 x 10⁶ cells/ml). Cells were stimulated with PHA-P (5 μg/ml) and cell-free supernatants were collected after 18 h and 48 h and stored at −20°C. They were analyzed by enzyme-linked immunosorbent assay (ELISA, Quantikine, R&D System, Minneapolis, MN, USA, sensitivity 4.2 pg/ml). The optical density was determined using a Thermomax microplate reader (Molecular Device Corp, Sunnyvale, CA, USA).
Dendritic Cells in HTLV-1 Infected Individuals

RESULTS

Generation and maturation of DC

Monocyte-derived DC were generated from the PBMC of healthy donors, asymptomatic HTLV-I carriers and ATLL patients. Although we had no information on HTLV-I carriers, we were able to isolate sufficient cells from the buffy coats supplied by Kochi Red Cross Blood Center to analyze DC, as well as lymphocytes. Efficient uptake of FITC-dextran was found at an im-
mature stage of DC in asymptomatic carriers and ATLL patients (data not shown). The phenotypic feature of mature DC was examined by flow cytometry and Figure 1 shows representative results. There was no significant difference in the phenotype of mature DC from fresh and cryopreserved cells from healthy donors (data not shown). CD1a expression was reduced in HTLV-I carriers and ATLL patients. Expression of HLA-DR was reduced in asymptomatic carriers. No substantial difference in the expression of CD11c, CD40, CD80, or CD86 was detected between HTLV-I infected individuals and healthy donors (data not shown).

**Aberrant stimulatory capacity of DC**

Comparative analyses have led to the suggestion that DC bear the unique ability to stimulate autologous T cells in the autologous mixed lymphocyte reaction\(^{17-20}\). Therefore, autologous proliferation may be due to the presence of FBS and the reaction merely reflects a specific response to an exogenous antigen during the culture period. Because we confirmed that T cells proliferated with irradiated DC in the presence of 10% FBS but not 10% plasma (data not shown), the aberrant function of mature DC as APC was assessed by co-culture of lymphocytes with autologous DC (Fig. 2). T cells were stimulated by autologous DC in half of the HTLV-I carriers as well as in the healthy donors. Interestingly, T cells did not respond in ATLL patients and suppression of spontaneous proliferation of ATLL cells was observed in a patient with acute ATLL (case 3).

**Functional defect of T cells**

To elucidate the other causes of immune suppression, T cell function was assayed by sCD40L expression. We compared several stimulators, including PHA-P, PMA+Ca\(^{2+}\) ionophore,

---

**Table 1** Measurement of soluble CD40 ligand (sCD40L) in the culture supernatant of lymphocytes after stimulation with PHA-P.

<table>
<thead>
<tr>
<th>Case</th>
<th>After 18h (pg/ml)</th>
<th>After 48h (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy donors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fresh</td>
<td>193.6 ± 155.5(^a)</td>
<td>624.8 ± 344.9(^a)</td>
</tr>
<tr>
<td>Cryopreserved</td>
<td>177.6</td>
<td>320.5</td>
</tr>
<tr>
<td>Asymptomatic carriers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 1</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Case 2</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Case 5</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Case 6</td>
<td>75.9</td>
<td>177.6</td>
</tr>
<tr>
<td>ATLL patients (Acute type)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 1</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Case 3</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>ATLL patient (Lymphoma-type)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(LN cells)</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>(Lymphocytes)</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Cell line (MT-2)</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

\(^a\)Average ± SD ; ND, not detectable.
anti-CD3 and anti-CD3+anti-CD28, and confirmed that PHA-P was the best stimulator for this experiment (data not shown). Following 18 h of activation with PHA-P, the production of sCD40L was detected in the supernatant of lymphocytes from 3 healthy donors and an asymptomatic carrier (case 6). Following 48 h of activation with PHA-P, the sCD40L concentration was elevated. The defect in the production of sCD40L was found in 3 of 4 asymptomatic carriers (cases 1, 2 and 5), all ATLL patients and MT-2 (Table 1).

**DISCUSSION**

Functional impairment of DC was demonstrated not only in ATLL patients but also in asymptomatic carriers. We found that CD1a and HLA-DR expression was suppressed in asymptomatic carriers. Recent studies have identified the CD1 family as a non-classical antigen presenting molecule that enables presentation of foreign lipids for specific T cell recognition, which suggests a role in the activation of cell-mediated immunity\(^{21}\). Because IL-10 exhibited DC inhibition at a relatively late stage of DC maturation\(^{22}\), significant production of this cytokine might be associated with our findings\(^{23}\). Our results suggest that partial impairment of DC maturation from HTLV-I carriers may be a cause of immune suppression.

We observed proliferation of lymphocytes with autologous DC from healthy donors as FBS affected autologous MLR (Fig. 2). In contrast, lymphocyte proliferation was detected in half of the HTLV-I carriers and none of the ATLL patients. These findings suggest that functional impairment of DC as APC frequently occur in HTLV-I infected individuals. We also found that spontaneous proliferation of T cells was suppressed from acute-type ATLL, suggesting that activation induces T cell death\(^{24}\). Because PHA triggered ATLL cell death in vitro, the spontaneous proliferation of ATLL cells may be due to T cell activation induced by cytokines or signaling via the CD3/TCR molecule complex (S. T., unpublished observations).

Like other members of the TNF superfamily, activated T cells can express both a membrane associated form and a soluble form of CD40L\(^{25}\). Both forms have the potential to be biologically active, and sCD40L can stimulate CD40 in a manner indistinguishable from the membrane-associated form of the protein\(^{26}\). It has been reported that CD40L expression is down regulated on T cells taken from ATLL patients\(^{27}\). We also observed a defect in the production of sCD40L in HTLV-I carriers, as well as in ATLL patients. CD40 expression by cognate DC was not necessary for initial T cell expansion but was essential to promote sustained expansion of T cells in vivo\(^ {28}\). No autologous proliferation of T cells with DC was seen in T cells that did not express sCD40L (Fig. 2 and Table 1). It seems that CD40L/CD40 interaction is important not only for DC maturation and activation but also for T cell proliferation in HTLV-I infected individuals. This defect may be exhibited as a result of immunosuppressive factors that negatively affect differentiation and terminal maturation of DC, as well as cellular immune response.

We showed that the maturation and function of DC as APC were frequently impaired in HTLV-I infected individuals. In addition, T cells from HTLV-I carriers expressed little CD40L. Immune suppression caused by such a network after HTLV-I infection may allow a small portion of infected cells to escape from the immune response as a pre-requisite for the leukemogenesis. Further studies are required to determine the reason. Our findings suggest that phenotypic and functional defects of DC are associated with ATLL development in a small percentage of HTLV-I carriers who are regarded as at high risk for ATLL.

**ACKNOWLEDGMENTS**

We thank Kenji Nishimori for preparing the buffy coat fraction from blood donors. We thank Isao Miyoshi for his critical reading of the manuscript. This work was supported in part by Grants-in-Aid for Cancer Research from the Ministry of Education, Science and Culture of Japan (# 12218104).

**REFERENCES**


2 Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita K-I, Shirakawa S and

